help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mauduit, C.
Right arrow Articles by Benahmed, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mauduit, C.
Right arrow Articles by Benahmed, M.
Endocrinology Vol. 142, No. 6 2509-2520
Copyright © 2001 by The Endocrine Society


ARTICLES

Leukemia Inhibitory Factor Antagonizes Gonadotropin Induced-Testosterone Synthesis in Cultured Porcine Leydig Cells: Sites of Action1

Claire Mauduit, Isabelle Goddard, Valérie Besset, Eric Tabone, Catherine Rey, Françoise Gasnier, Françoise Dacheux and Mohamed Benahmed

INSERM U. 407, Communications Cellulaires en Biologie de la Reproduction (C.M., I.G., V.B., M.B.), and INSERM U. 189 (C.R., F.G.), Faculté de Médecine Lyon Sud, 69921 Oullins Cedex, France; URA INRA-CNRS 1291, PRMD, Nouzilly, France (F.D.)

Address all correspondence and requests for reprints to: Dr. C. Mauduit, Institut National de la Santé et de la Recherche Médicale U 407, Communications Cellulaires en Biologie de la Reproduction, Faculté de Médecine Lyon Sud, BP 12, 69921 Oullins Cedex, France. E-mail mauduit{at}lsgrisnl.univ-lyon1.fr


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In the present report, the action of leukemia inhibitory factor (LIF) on testicular steroid hormone formation was studied. For this purpose, the direct effects of LIF were evaluated on basal and human (h)CG-stimulated testosterone synthesis by cultured, purified Leydig cells isolated from porcine testes. LIF reduced (more than 60%) hCG-stimulated testosterone synthesis. This inhibitory effect was exerted in a dose- and time-dependent manner. The maximal and half-maximal effects were obtained with, respectively, 10 ng/ml (0.5 nM ) and 2.5 ng/ml (0.125 nM ) of LIF after a 48-h treatment of the Leydig cells. Such an effect of the cytokine was not a cytotoxic effect, because it was reversible and Leydig cells recovered most of their steroidogenic activity after the removal of LIF. Considering the sites of action of LIF in inhibiting gonadotropin-stimulated testosterone formation, it was shown that LIF significantly (P < 0.002) reduced, in a comparable range (about 60% decrease), testosterone synthesis stimulated with LH/hCG or with pharmacological agents that enhance cAMP levels (cholera toxin, forskolin, and PG E2), and testosterone synthesis stimulated with 8-bromo-cAMP. Such an observation indicates that the antigonadotropic action of the cytokine is exerted in a predominant manner at a step (or steps) located beyond cAMP formation. Furthermore, incubation of Leydig cells with 22R-hydroxycholesterol (5 µg/ml, 2 h), a cholesterol substrate derivative that does not need an assisted process to be delivered to the inner mitochondrial membrane, reversed most of the inhibitory effect of LIF on the steroid hormone formation. Such results indicate that LIF acts by reducing cholesterol substrate availability in the mitochondria. Consequently, LIF action was tested on steroidogenic acute regulatory protein and PBR (peripheral benzodiazepine receptor) shown to be potentially involved in such a cholesterol transfer. LIF reduced, in a dose- and time-dependent manner, LH/hCG-induced steroidogenic acute regulatory protein messenger RNA levels. The maximal inhibitory effect was obtained with 6.6 ng/ml of LIF after 48 h of treatment. In contrast, LIF had no effect on PBR messenger RNA expression or PBR binding. This inhibitory effect of LIF on Leydig cell steroidogenesis is probably exerted via an auto/paracrine action of the cytokine. Indeed, by immunohistochemistry, LIF and LIF receptor proteins were identified in Leydig and Sertoli cells but not in other testicular cell types, except for LIF receptor in spermatogonia. Furthermore, the presence of LIF and its receptor in Leydig cells at the neonatal and adult periods suggests that the inhibitory effect of LIF on androgen formation reported here probably occurs in both the fetal and the adult Leydig cell populations during testicular development.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
LEUKEMIA INHIBITORY FACTOR (LIF) is a secreted polyfunctional cytokine of the interleukin (IL)-6 family sharing the common gp 130 receptor subunit together with IL-6, IL-11 oncostatin M ciliary neurotrophic factor and cardiotrophin (for a review, see 1). The LIF receptor (LIF R) is a class I cytokine receptor belonging to the hematopoetic cytokine receptor super family (for a review, see 1). LIF elicits a diversity of biological effects on many cell types, including embryonic stem cells, primordial germ cells, neurones, adipocytes, hepatocytes, and osteoblasts (for reviews, see 2, 3, 4, 5). LIF affects various endocrine cell types (utero-placenta unit, bone metabolism, adrenal, ovarian, and testicular). LIF modulates the hypothalamus-pituitary-adrenal (HPA) axis activity and has strong physiological implications in the HPA axis response to stress and inflammation (1). LIF enhances basal and ACTH-induced production of cortisol and aldosterone in adrenal carcinoma cell line (6). It has been suggested that LIF-mediated activation of the HPA axis, both at the level of pituitary (reviewed in 1) and the adrenal (6), could act synergistically to counteract an uncontrolled immune response.

Specifically, in the reproductive systems, LIF is an important cytokine in early pregnancy. Indeed, female LIF knock-out mice are infertile because of a defect in the process of embryonic implantation (5, 7, 8, 9). Cultured granulosa cells from mature follicle, but not from immature follicle, exhibit an increase in LIF production after ßhCG (ß-human CG) (10), suggesting that LIF might be involved in ovulation and final oocyte development (11). In the testis, LIF has been shown to promote primordial germ cell proliferation (12, 13, 14) and to enhance survival of gonocytes (15) and Sertoli cells (16). In the present paper, we report on a novel biological activity of this cytokine in the testis, the inhibition of Leydig cell steroidogenesis. Indeed, by using cultured porcine Leydig cells as a model, we: 1) show that LIF is a potent inhibitor of steroid hormone formation; and 2) further localize the site(s) of action of the cytokine to the transport of cholesterol substrate into mitochondria.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials
hCG (CR 127 13450 IU/mg) was a gift from Dr. A. F. Parlow (NHPP, Torrance, CA). DMEM, Ham’s F-12 medium, and Moloney murine leukemia virus (M-MLV) were obtained from Life Technologies, Inc. (Eragny, France). Collagenase/dispase, SalI, nylon membrane (positively charged), CPD Star, Dig RNA labeling kit, blocking reagent, and anti-DIG AP (digoxigenin alkaline phosphatase) antibody were obtained from Roche Molecular Biochemicals (Meylan, France). Human recombinant leukemia inhibiting factor (LIF) was obtained from Pepro Tech (Canton, MA). 22R-hydroxycholesterol (5-cholestene-3ß,22(R)-diol: 22R-hydroxycholesterol), pregnenolone, dehydroepiandrosterone (DHEA), androstenedione, 8-bromo-cyclic AMP (8-bromo-cAMP), forskolin (7ß-acetoxy-8,13-epoxy-1{alpha}, 6ß, 9{alpha}-trihydroxy-labd-14-en-11-one), cholera toxin, insulin, transferrin, vitamin E, HEPES (4-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) and deoxyribonuclease type I were purchased from Sigma (St. Louis, MO). Oligonucleotide primers were obtained from Genset (Paris, France), and Taq polymerase was purchased from Promega Corp. (Lyon, France). LIF R rabbit polyclonal antibody (sc-659) and LIF goat polyclonal antibody (sc-1339) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). [3H]PK11195 was obtained from NEN Life Science Products (Boston, MA). Horseradish peroxidase-labeled goat or rabbit antibodies, and Covalight reagent, were purchased from Covalab (Lyon, France).

Leydig cell preparation and culture
Isolated Leydig cells were prepared from immature porcine testes (2–3 weeks old) by collagenase treatment as previously reported (17). Briefly, decapsulated testes were minced and washed in DMEM/Ham’s F-12 medium (1:1). After collagenase dissociation (0.5 mg/ml, 90 min at 32 C), cells were washed by centrifugation (200 x g for 10 min). The pellet was then resuspended and submitted to two successive sedimentations of 5 and 15 min. The crude interstitial cells were recovered from the supernatants, and Leydig cells were prepared from this fraction by Percoll gradient centrifugation. The purity of Leydig cells was more than 90%, as determined by histochemical 3ß-hydroxysteroid dehydrogenase staining (18). Leydig cells were plated in Falcon (Los Angeles, CA) 24-multiwell plates (0.5 x 106 cells/dish) and cultured at 32 C in a humidified atmosphere of 5% CO2–95% air in DMEM/Ham’s F-12 medium (1:1) containing sodium bicarbonate (1.2 mg/ml), 15 mM HEPES, and gentamicin (20 µg/ml). This medium was supplemented with insulin (2 µg/ml), transferrin (5 µg/ml), and vitamin E (10 µg/ml). At the end of the experiments, the culture medium was collected and stored at -20 C until assayed for steroid hormone content.

Leydig cell steroidogenic activity
Cultured porcine Leydig cell steroidogenic activity was mainly evaluated through the secretion of testosterone. The main characteristic of this culture system was that the secretion of this hormone in response to LH/hCG remains high and stable for several days and particularly between day 2 and day 6 of culture. Because, in cultured porcine, Leydig cells’ accumulation of unconjugated steroids is close to linear only during the first 4 h (19 and our unpublished data), the steroidogenic capacity of these cells was tested, after a 3-h stimulation with hCG, on day 6 of culture.

For the determination of steroidogenic enzyme activities, cultured Leydig cells were incubated with a hydroxylated cholesterol derivative (22R hydroxycholesterol), which can readily diffuse across the mitochondrial membranes and the aqueous space between membranes and can be used as a substrate for the mitochondrial cholesterol side chain cleavage enzyme activity (cytochrome P450scc) (20). The other steroidogenic enzyme activities were determined by incubation with different steroid substrates: pregnenolone, DHEA, and androstenedione. Porcine Leydig cells use the following pathway for testosterone biosynthesis: cholesterol {Rightarrow} pregnenolone {Rightarrow} 17{alpha} hydroxypregnenolone {Rightarrow} DHEA {Rightarrow} {Delta}4 androstenedione {Rightarrow} testosterone. To assess whether LIF affects this steroidogenic pathway, cultured Leydig cells (in the absence or presence of LIF) were incubated with different steroid substrates i.e. 22Rcholesterol, pregnenolone, DHEA, and {Delta}4 androstenedione, which are used for testosterone synthesis. Testosterone levels were measured in the culture medium by using a previously reported specific RIA (21).

RNA extraction
Total RNA was extracted from porcine Leydig cells with TRIzol reagent, a monophasic solution of phenol and guanidine isothiocyanate. This reagent is an improvement to the single-step RNA isolation developed by Chomczynski and Sacchi (22). The amount of RNA was estimated, by spectrophotometry, at 260 nm.

RT-PCR analysis
Single-stranded complementary DNAs (cDNAs) were obtained from RT of 1.5 µg total RNA using random hexanucleotides as primers (5 µM), in the presence of deoxynucleotides (200 µM), dithiothreitol (10 mM), and M-MLV (10 U/µl), for 1 h at 37 C. cDNAs (1 µl RT mixture) were amplified by PCR with Taq polymerase (0.01 U/µl), deoxynucleotides (50 µM), 0.75 µCi [{alpha}-33P]deoxy-ATP, and specific primers (1 µM). The mixture was first heated at 94 C for 5 min and then X cycles of 94 C for 30 sec, Tm (melting temperature) for 30 sec, 72 C for 30 sec, then 72 C for 5 min (see Table 1Go). PCR products were analyzed on an 8% polyacrylamide gel. Dried gels were exposed to Biomax MR-1 films (Eastman Kodak Co., Rochester, NY) for 1–2 days at room temperature. Intensity of bands was estimated by densitometric scanning using the BioImage scanner (BioImage, Cheshire, UK). The data were expressed by steroidogenic acute regulatory protein (StAR)/ßactin or peripheral benzodiazepine receptor (PBR)/ßactin messenger RNA (mRNA) ratio.


View this table:
[in this window]
[in a new window]
 
Table 1. Sequence of primer used for RT-PCR experiments

 
PCR analyses were carried out from the logarithmic phase of amplification. PCR amplified products were checked by direct sequencing. RT-PCR primers were designed inside separate exons to avoid any bias caused by residual genomic contamination. Moreover, for all primers, no amplification was observed when PCR was performed on RNA preparations.

Northern blotting analysis
About 15 µg total RNAs [denatured 15 min at 65 C in the presence of formaldehyde (2.2 M), formamide (12.5 M), 1x 3(N-morpholino)propanesulfonic acid] were electrophoresed on 1.2% agarose/2.2 M formaldehyde gels. After migration in 0.02 M 3(N-morpholino)propanesulfonic acid running buffer, RNAs were transferred onto a nylon membrane in 10x SSC (1.5 M NaCl, 0.15 M sodium citrate) and fixed at 80 C for 2 h. The plasmid containing the StAR cDNA (kindly given by Dr. D. M. Stocco, Texas Tech University Health Sciences Center, Lubbock, TX) was linearized with SalI. The StAR DIG-labeled riboprobe was obtained by in vitro transcription using the Sp6 enzyme according to the manufacturer’s recommendations. The nylon membranes were prehybridized for 1 h at 68 C, and the filters were then hybridized with StAR RNA DIG-labeled probe (100 ng/ml) overnight at 68 C in 50% formamide, 5x SSC, 2% blocking reagent, 0.02% SDS, and 0.1% N-lauryl sarcosin. Afterwards, membranes were washed twice in 2x SSC, 0.1% SDS (5 min, at room temperature), followed by 15 min at 68 C in 0.1x SSC, 0.1% SDS. The filters were then equilibrated for 1 min in buffer 1 [maleic acid (100 mM), NaCl (150 mM), pH 7.5] and blocked for 30 min in buffer 1 containing 1% blocking reagent. The antibody (anti-DIG AP) was diluted (1:10,000) in blocking solution and incubated for 30 min with the filters. The membranes were washed twice in buffer 1 (15 min, at room temperature) and equilibrated in detection buffer [Tris (100 mM), NaCl (100 mM), pH 9.5]. Detection was performed with CPD Star chemiluminescent substrate solution at a 1:100 dilution in detection buffer (5 min, at room temperature). Filters were autoradiographed for 15 min. After dehybridation [formamide (80%), Tris-HCl (pH 8, 50 mM), SDS (1% for 2 x 30 min at 75 C)], the filters were hybridized with an 18S RNA DIG-labeled probe (20 ng/ml) as described above. Intensities of autoradiographic bands were estimated by densitometric scanning using the BioImage scanner. The data were expressed as StAR/18S mRNA ratios.

Radioligand binding assays for PBR
Leydig cell cultures were washed with medium, scraped from the dishes, and collected by centrifugation at 180 x g for 10 min. PK 11195 was used as a ligand for PBR. [3H]PK11195 binding studies on 20 µg of proteins from cell suspensions in Tris-buffered saline (TBS) were performed at 0 C in a final incubation vol of 0.25 ml, using 0.9 nM of the radiolabeled ligand. Nonspecific binding was determined in the presence of 10-5 M unlabeled ligand. After 30 min incubation, the assays were stopped by filtration through GF/C filters (Whatman, Maidstone, UK) pretreated with 10 µM unlabeled ligand and washed with 15 ml ice-cold PBS. Radioactivity trapped on the filters was determined by liquid scintillation counting. Total binding was approximately 10% of the total free radioligand included in the assay, and specific binding was 90% of the total binding.

Western blot analysis
StAR protein contents were identified in isolated mitochondria; PBR, LIF, and LIF R protein contents were identified in whole Leydig cells. For isolation of crude mitochondria, the harvested Leydig cells were pelleted by centrifugation at 200 x g for 10 min. The pelleted cells were resuspended in ice-cold buffer A, consisting of 275 mM sucrose, 10 mM Tris-HCl (pH 7.4), and 1 mM EDTA (0.5 ml of buffer/75 x 106 cells) and homogenized with a Teflon homogenizer. Cell debris and nuclei were removed from homogenates by centrifugation at 960 x g for 15 min. The pellet was resuspended in buffer A, homogenized, and centrifuged under the same conditions. The supernatants were pooled and centrifuged at 8,600 x g for 15 min to yield the mitochondrial pellet. To purify mitochondria, the crude mitochondrial pellet was suspended in isolation buffer and centrifuged at 960 x g for 3 min. The resultant supernatant was centrifuged twice at 8,600 x g for 15 min.

Proteins from whole Leydig cells (30 µg) or from mitochondria (80 µg) were resolved on 5% (LIF R), 10% (LIF), or 12% (StAR, PBR) SDS/polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes using 25 mM Tris, 185 mM glycine (pH8.3) containing 20% methanol. The transfer was performed at a constant voltage of 100 V for 1 h. After transfer, the membranes were incubated in blocking buffer (TBS buffer containing 5% blocking reagent) for 1 h at room temperature. The membranes were rinsed three times with TBS and incubated with primary antibody (1/100, 1/250, 1/500, 1/1000 dilution in TBS containing 2% blocking reagent for LIF R, LIF, StAR, and PBR, respectively) overnight at +4 C. The membranes were rinsed with TBS/Tween 0.1% (3 x 10 min) and then incubated with horseradish peroxidase-labeled goat or rabbit antibodies (1/2000 degree). Bound antibodies were detected by chemiluminescence using a Covalab kit and Biomax MR-1 films (Eastman Kodak Co.).

Immunohistochemistry
Large White boars obtained from INRA (Nouzilly, France) were electrocuted and immediately bled. Testes from 15-, 21-days-postpartum (perinatal), 3.5-months (prepubertal), and 6.5-months (adult) animals were removed and fixed overnight in 4% paraformaldehyde in PBS and postfixed in aqueous Bouin for 6 h at room temperature. Paraffin sections (5 µM) of Bouin-fixed testis were mounted on glass slides. The sections were deparaffinized and rehydrated. The UltraVision Detection System (Lab Vision Corp., Fremont, CA) was used as recommended by the manufacturer. Briefly, endogenous peroxidases were blocked with 3% H2O2 for 15 min. The sections were incubated for 5 min with a protein-blocking solution to minimize nonspecific binding. The primary antibody was diluted (LIF, 1:100; LIF R, 1:250) in antibody diluant (DAKO Corp., Trappes, France) and incubated with the sections for 2 h at room temperature. After washing and incubation with the biotinylated secondary antibody, a peroxidases streptavidin complex was applied. 3,3'-Diaminobenzidine was used as a peroxidases chromogen. Sections were briefly counterstained with Harris hematoxylin and mounted in mounting medium. The same antibodies were used for immunohistochemistry and Western blot analyses. Negatives controls were performed by using saturated antibodies with corresponding immunogenes. The saturation was performed by preincubating (6 h at 4 C) the usual antibody dilution with a 5-fold concentration of the immunogene peptide.

Data analysis
All experimental data are presented as the mean ± SD of triplicate determinations of steroid production by three replicate cultures within each treatment group. Triplicates were handled as three independent values. All experiments reported here were repeated at least three times with independent cell preparations. A representative experiment of each series is presented. Statistical significance between groups was determined by Student’s t test using the StatWorks (Hyden and Son Ltd, London, UK) package on a Macintosh computer. Differences are accepted as significant at P < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
LIF inhibits LH/hCG-stimulated testosterone synthesis in cultured Leydig cells
To assess the possibility that LIF may affect testosterone biosynthesis, Leydig cells were cultured in the absence or presence of increasing doses of LIF (0.2–60 ng/ml, 72 h) before being acutely (3 h) stimulated with a maximally efficient hCG dose (3 ng/ml) (Fig. 1AGo). The maximal and half-maximal inhibitory effects were observed, respectively, with 10 ng/ml and 2.5 ng/ml LIF (Fig. 1AGo). Such an inhibitory effect of LIF was time-dependent and was maximal (P < 0.01) after 48 h with LIF (25 ng/ml) (Fig. 1BGo). Finally, as shown in Fig. 1CGo, the inhibitory action of LIF (25 ng/ml, 72 h) was observed on testosterone synthesis stimulated with different gonadotropin concentrations (0.01–9 ng/ml). LIF affected the maximal steroidogenic capacity of Leydig cells but not the ED50 of hCG (0.1 ng/ml) required to stimulate testosterone synthesis.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 1. Inhibitory effects of LIF on LH/hCG-stimulated testosterone formation in cultured Leydig cells. Leydig cells were cultured: for 72 h, in the absence or presence (•) of increasing concentrations (0.2–60 ng/ml) of LIF, then stimulated for 3 h with a maximal efficient dose of hCG (3 ng/ml) (A); for the duration indicated (2–72 h), in the absence ({square}) or presence ({blacksquare}) of LIF (25 ng/ml), and then simulated with hCG (3 ng/ml, 3 h) (B); for 72 h, in the absence ({circ}) or presence (•) of LIF (25 ng/ml), and then stimulated with increasing doses of hCG (0.01–9 ng/ml, 3 h) (C). The results represent the mean ± SD of three separate determinations in three different dishes.

 
The inhibitory action of LIF did not result from Leydig cell damage, as demonstrated by the data shown in Fig. 2Go. Indeed, the removal of the cytokine from Leydig cell culture medium resulted in a gradual and progressive recovery of most of the hCG-stimulated testosterone levels. The inhibition of hCG-induced androgen production decreased gradually from 57% of inhibition at the moment after the removal of LIF (day 0) to only 14% of inhibition 72 h after the removal of the cytokine (Fig. 2Go). Furthermore, the number of Leydig cells cultured in the presence or absence of LIF (25 ng/ml, 72 h) was not affected (data not shown).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. Recovery of Leydig cell steroidogenesis after LIF removal. Leydig cells were initially cultured for 24 h, in the absence ({square}) or presence ({blacksquare}) of LIF (25 ng/ml). The culture media were then removed, and the cells were washed and stimulated with hCG (3 ng/ml, 3 h) (day 0) or reincubated with LIF-free medium for an additional 24 h, 48 h, or 72 h. At the end of each incubation, the cells were stimulated with hCG (3 ng/ml, 3 h). The results represent the mean ± SD of three separate determinations in three different dishes.

 
Mitochondrial transfer of cholesterol as a site of action of LIF
The inhibitory effects of the cytokine on testosterone production were similarly observed whether Leydig cells were stimulated with the gonadotropin or with different pharmacologic agents that enhance cAMP levels, including cholera toxin, forskolin, and PGE2. The inhibitory effects (P < 0.002) on testosterone production were of 70%, 66%, and 65% for cholera toxin, forskolin, and PGE2, respectively (Fig. 3AGo). These findings suggest that LIF interferes with cAMP production and/or action. The significant (P < 0.002) and dramatic decline (about 60% decrease) in testosterone biosynthesis, similarly observed in LIF-treated Leydig cells stimulated with 8-bromo-cAMP (3 mM, 3 h) (Fig. 3BGo), indicates that the cytokine affects Leydig cell steroidogenesis at a biochemical step (or steps) located beyond cAMP formation.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 3. Effects of LIF on steroid hormone formation in Leydig cells cultured in the presence of stimulators of cAMP formation (cholera toxin, forskolin, and PGE2) or testosterone steroid substrates (22R hydroxycholesterol, pregnenolone, DHEA, {triangleup}4 androstenedione). Leydig cells were cultured in the absence ({square}) or the presence ({blacksquare}) of LIF (25 ng/ml, 72 h) before: being stimulated for 3 h with hCG (3 ng/ml) or cholera toxin (CT) (10 µg/ml) or forskolin (Fsk) (50 µM) or PGE2 (1 µM) (A); being stimulated with hCG (3 ng/ml) and 8-bromo-cAMP (cAMP) (3 mM) (B); being incubated with 22R hydroxycholesterol (22Rchol) (5 µg/ml, 2 h) or pregnenolone ({triangleup}5P) (500 ng/ml, 2 h) or DHEA (500 ng/ml, 2 h) or {triangleup}4 androstenedione ({triangleup}4P) (500 ng/ml, 1 h) (C). The results represent the mean ± SD of three separate determinations in three different dishes.

 
To further identify the post-cAMP site of action of LIF, Leydig cells were incubated with different steroid substrates, including 22R-hydroxycholesterol (a cholesterol substrate derivative that does not need an assisted process to be delivered to the inner mitochondrial membrane), {Delta}5 pregnenolone, DHEA, and {Delta}4 androstenedione. As shown in Fig. 3CGo, in the presence of these substrates, the inhibitory effect of LIF on testosterone formation was no longer observed. These observations indicate that the potent inhibitory effect of the cytokine on the gonadotropin action occurs at a step(or steps) related to cholesterol transport/availability in the mitochondria rather than to cholesterol conversion into steroid hormones. Specifically, the disappearance of the inhibitory action of the cytokine on testosterone formation in the presence of 22R-hydroxycholesterol suggests that LIF may exert its inhibitory action on cholesterol substrate transport. Because two proteins (StAR and PBR) have been mainly involved in the cholesterol transport, we further examine the effect of LIF on their expression.

LIF inhibited, in a dose-dependent manner, StAR mRNA levels, as shown by the RT-PCR approach. The maximal inhibitory effect (P < 0.03) of LIF was observed with 6.6 ng/ml (Fig. 4AGo). The inhibitory action of LIF on StAR expression was also time-dependent, with a maximal effect observed at 48 h (Fig. 4BGo). The inhibitory effect of LIF on StAR was confirmed by identification and quantification of StAR mRNA through Northern blotting analysis (mRNA size, 4.4 kb) (Fig. 4CGo) and identification of StAR protein (30 kDa) through Western blotting (Fig. 5BGo). In contrast, PBR mRNA levels were not modified by LIF at the different doses and times tested (Fig. 6Go, A and B). Similarly, PBR binding (Fig. 6CGo) and PBR (18 kDa) protein content (Fig. 5AGo) were not affected by LIF at the different doses (0.07–20 ng/ml, 72 h) tested.



View larger version (39K):
[in this window]
[in a new window]
 
Figure 4. Effects of LIF on StAR expression. Leydig cells were cultured: for 72 h without (basal, hCG) or with increasing concentrations (0.07–20 ng/ml) of LIF, then stimulated for 3 h with hCG (3 ng/ml) (except for basal) (A); for the duration indicated (6–72 h) without (hCG) or with LIF (20 ng/ml) then stimulated with hCG (3 ng/ml, 3 h) (B); without treatment (basal) or in presence of hCG (3 ng/ml, 3 h) or in presence of LIF (20 ng/ml, 48 h) and hCG (3 ng/ml, 3 h) (C). Upper panel, Results (histograms) represent the mean ± SD of three separate determinations; lower panel, a representative RT-PCR (A, B) and a representative Northern blot (C) are shown.

 


View larger version (43K):
[in this window]
[in a new window]
 
Figure 5. Effects of LIF on StAR and PBR protein contents. Leydig cells were cultured for 72 h without (basal, hCG) or with LIF (20 ng/ml), then stimulated for 4 h with hCG (3 ng/ml). At the end of incubation, the cells were treated as described under Materials and Methods to detect PBR protein content in whole Leydig cells (A) and StAR protein content in mitochondria (B).

 


View larger version (42K):
[in this window]
[in a new window]
 
Figure 6. Effects of LIF on PBR mRNA expression and PBR binding. Leydig cells were cultured: for 72 h without (basal, hCG) or with increasing concentrations (0.07–20 ng/ml) of LIF, then stimulated for 3 h with hCG (3 ng/ml, except for basal) (A); for the duration indicated (6–72 h) without (basal, hCG) or with LIF (20 ng/ml), then stimulated with hCG (3 ng/ml, 3 h, except for basal) (B). Upper panel, Results (histograms) represent the mean ± SD of three separate determinations; lower panel, a representative RT-PCR (A, B) is shown. C, Leydig cells were cultured for 72 h without treatment (basal), in the presence of LIF (20 ng/ml) or with increasing concentrations (0.07–20 ng/ml) of LIF, then stimulated for 3 h with hCG (3 ng/ml, hCG and LIF+hCG).

 
LIF and LIF R expression during porcine testicular development
To determine the developmental context in which the inhibitory effects of LIF are exerted on Leydig cell steroidogenic activity, LIF and LIF R proteins were identified in porcine testes. Three periods that are critical in the porcine testis development have been selected: 15 and 21 days (neonatal), 3.5 months (prepubertal), and 6.5 months (adult). LIF was detected by immunohistochemistry in Leydig cells at 15 days, 21 days, 3.5 months, and 6.5 months (Fig. 7Go, a–d). In the seminiferous tubules, LIF was detected exclusively in Sertoli cells at 3.5 and 6.5 months (Fig. 7Go, a–d). The presence of LIF mRNA (Fig. 8CGo) and LIF protein (Fig. 8CGo) were evidenced in isolated and purified Leydig and Sertoli cells from 21-day-old porcine testes.



View larger version (175K):
[in this window]
[in a new window]
 
Figure 7. Localization of LIF by immunohistochemistry. Porcine testis sections were incubated with LIF antibody (1:100). a, 15 days postpartum (perinatal); b, 21 days postpartum (perinatal); c, 3.5 months postpartum (prepubertal); d, 6.5 months postpartum (adult). Bar, 100 µM.

 


View larger version (36K):
[in this window]
[in a new window]
 
Figure 8. LIF and LIF R expression in Leydig cells (LC) and Sertoli cells (SC). After protein extraction from cultured Sertoli or Leydig cells (21 days post partum), Western blot analysis was conducted as described under Materials and Methods to identify LIF (A) and LIF R (B). Negative controls were performed by using saturated antibodies (Ab) with corresponding immunogenes (peptide). C, After extraction of RNAs from cultured Sertoli or Leydig cells (21 days post partum), RT-PCR experiments were conducted as described under Materials and Methods to identify the presence of LIF and LIF R mRNA.

 
The LIF R was detected by immunohistochemistry in Leydig cells at 15 days, 21 days, 3.5 months, and 6.5 months (Fig. 9, a–d). In the seminiferous tubules, LIF R was observed in Sertoli cells (21 days, 3.5 months, and 6.5 months) and spermatogonia (6.5 months) (Fig. 9Go, a–d). Moreover, the LIF R was detected in isolated and purified Leydig and Sertoli cells from 21 days, in terms of mRNA (Fig. 8CGo) and protein (Fig. 8BGo).



View larger version (175K):
[in this window]
[in a new window]
 
Figure 9. Localization of LIF R by immunohistochemistry. Porcine testis sections were incubated with LIF R antibody (1:250). a, 15 days postpartum (perinatal); b, 21 days postpartum (perinatal); c, 3.5 months postpartum (prepubertal); d, 6.5 months postpartum (adult). Bar, 100 µM.

 
The signal for LIF and LIF R disappeared when using saturated antibodies with corresponding immunogenes in Western blotting (Fig. 8Go) and immunohistochemistry (data not shown) approaches.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The present findings demonstrate a novel role of LIF as a potent inhibitor of steroid hormone synthesis in cultured Leydig cells under acute gonadotropin stimulation.

The inhibitory effect of LIF on Leydig cell steroidogenesis was not exerted in a context of a toxic or deleterious action of the cytokine on the testicular steroidogenic cells. Indeed, LIF was without significant effect on Leydig cell number, and its inhibitory effect was reversible. The reversibility of LIF action was shown by the capacity of Leydig cells to recover most of their steroidogenic activity in response to gonado-tropin stimulation after removal of the cytokine. This indicates that, in the experimental conditions used in this study, LIF has a specific (noncytotoxic) regulatory action on Leydig cell steroidogenic activity. Furthermore, the inhibitory effect of LIF on the gonadotropin-stimulated testicular testosterone production may result from a direct interaction between the cytokine and the steroidogenic cells. Such an observation is supported by the identification of LIF R in postnatal porcine Leydig cells, in terms of mRNA identified through RT-PCR approach and protein identified through immunohistochemical and Western blotting analyses.

Considering the biochemical mechanisms and the molecules involved in the inhibitory effect of the cytokine on the gonadotropin-induced androgen production, the major site(s) of action of the cytokine seems to be located at a post-cAMP level. The similar dramatic decrease in hormonal production (in LIF-pretreated Leydig cells) observed after an acute stimulation with LH/hCG or with cAMP formation stimulators (e.g. cholera toxin, PGs, forskolin) indicates that the inhibitory action of LIF might be related to cAMP formation and/or action. The fact that testosterone synthesis was similarly and dramatically reduced in LIF-treated Leydig cells stimulated either with the gonadotropin or with 8-bromo-cAMP suggests a predominant action of the cytokine at a site(s) located beyond cAMP generation. Furthermore, incubation of Leydig cells with 22R-hydroxycholesterol (a cholesterol derivative that can readily diffuse across the mitochondrial membranes and the aqueous space between membranes to be delivered to P450scc) reversed most of the inhibitory effect of LIF. These observations suggest that LIF antagonizes the gonadotropin hormonal action predominantly by decreasing cholesterol substrate transport and/or availability for cytochrome P450scc activity in the inner mitochondria.

In steroidogenic tissues, and particularly in Leydig cells, cholesterol transport can be thought of as occurring in two separate processes. The first part of this process is the mobilization of cholesterol from cellular stores to the outer mitochondrial membrane, whereas the second part consists of the transfer of cholesterol from the outer to the inner mitochondrial membrane (for review, see 23, 24). It is now accepted that the rate-limiting step regulated by LH/hCG is the delivery of cholesterol to P450scc (for review, see 24). Although all the mechanisms involved in the cholesterol delivery to P450scc are not completely understood, recent years have brought enlightenment and two strong candidates: StAR and PBR. Different arguments suggest the involvement of StAR in such a process. Indeed, the StAR protein is expressed in steroidogenic tissues and is up-regulated by trophic hormones, and particularly LH/hCG, in Leydig cells (25). StAR protein has been shown to be associated with the mitochondria (26). A strong evidence for the role of StAR in cholesterol transfer was the finding that mutations in the StAR gene result in a disease named congenital lipoid adrenal hyperplasia, in which an almost-complete blockade of steroid hormone synthesis was observed (27). The generation of StAR knock-out mice showed a phenotype identical to that of the human disease (28). These data strongly support the involvement of StAR in cholesterol delivery to P450scc. Although, the mechanisms of action of StAR are not entirely known, mutation studies showed that the C-terminal region of StAR supports the cholesterol transfer function of the protein (29). Moreover, StAR is synthesized as a 37-kDa precursor and has to be phosphorylated to produce its full activity (30). Concerning PBR, although present in all tissues examined, it was found to be particularly high in steroid producing tissues (for a review, see 31). In these tissues, PBR is primarily localized in the outer mitochondrial membrane and preferentially located in the outer/inner membrane contact sites involved in the cholesterol delivery to P450scc (32). It has been shown that mitochondrial ligand binding to PBR is sensitive to hormone treatment (33). Moreover, targeted disruption of the PBR gene in Leydig cells resulted in the arrest of cholesterol transport into mitochondria and steroid formation, whereas transfection of the mutant cells with PBR cDNA rescued steroidogenesis (34). These data suggest that PBR is involved in cholesterol transfer to the mitochondrial inner membrane, and molecular modeling of PBR suggests that it might function as a channel for cholesterol (35). Recently, a consensual hypothesis suggested that PBR could interact with StAR to promote cholesterol transfer (24).

In the present study, we showed that LIF was an inhibitor of StAR expression at the levels of mRNA and protein. In contrast, LIF did not modulate PBR mRNA expression, PBR binding, and PBR protein contents. Thus, the inhibitory action of LIF on LH/hCG-induced testosterone synthesis might be mainly attributable to a decrease in StAR expression. In addition, we showed in our porcine Leydig cell model that, in contrast with the murine model (33), hCG did not enhance PBR expression. These discrepancies could be attributed to interspecies specificity but could not be accounted for by an absence of PBR regulation in porcine Leydig cells, because we recently demonstrated that PBR expression is increased after TNF{alpha} treatment in porcine-cultured Leydig cells (36). It is of interest to note that different recent reports have indicated that StAR expression is targeted by a large number of molecules that affect gonadotropin-induced testosterone formation in Leydig cells. Different cytokines, including transforming growth factor ß (our unpublished data), IL-1ß (37), tumor necrosis factor-{alpha} (38), and interferon{gamma} (39), have been reported to exert their inhibitory action on LH/hCG-induced testosterone production through a decrease in StAR expression. Moreover, injection of LPS, which is a potent inductor of cytokine secretion, decreases StAR expression in Leydig cells (40). Other signaling molecules, such as insulin-like growth factor I (41), CRH (42), T3 (43), GH (44), and retinoic acid (45), enhanced LH/hCG-induced testosterone formation by increasing StAR expression. Finally, more recently, pesticides [such as lindane (46) and dimethoate (47)] have been shown to inhibit Leydig cell steroidogenesis through a decrease in StAR expression.

LIF and IL-6 family-related cytokines bind to specific cell surface receptors that are coupled to a common gp 130 signal transducing receptor component in diverse cell types and induce the homodimerization of the gp 130 protein with the IL-6 receptor chain (in the case of IL-6) or heterodimerization of gp 130 and the LIF R component (in the case of LIF, ciliary neurotrophic factor, cardiotrophin, and oncostatin M). Upon binding to these receptors, the cytokine triggers a rapid intracellular tyrosine phosphorylation of the gp 130 protein, Janus kinase (JAK) 1, JAK 2, and tyrosine kinase 2. These phosphorylations activate the signal transducer and activator of transcription (STAT-3/STAT-1) signal transduction (for review, see 48, 49). Although in the present report we have shown that LIF R is expressed in testicular Leydig cells, the transducing systems used by LIF to regulate StAR expression remain to be identified. Considering the mechanisms involved in the negative effect of LIF on StAR mRNA levels, it might be attributable to a decrease in the transcriptional activity and/or mRNA stability. LIF may affect StAR gene expression through interactions with transcriptional factors that might bind to the StAR gene promoter. In this context, LIF may antagonize cAMP production and/or cAMP action (the present data) and therefore the induction of proteins that regulate StAR gene transcription such as SF-1 (steroidogenic factor-1), previously shown to control StAR gene expression (50, 51, 52).

Whether the in vitro data presented here reflect a potential physiological or pathological role of LIF in the male gonad function required further studies. To answer this question, we have performed, as a first step, the identification of LIF and LIF R proteins during porcine testis development at three critical periods: neonatal, prepubertal, and adult periods. LIF and LIF R proteins were identified by using immunohistochemical and Western blot analyses. During testicular development, immunoreactive LIF and LIF R were identified in Leydig and Sertoli cells but not in the other testicular cell types, except for the presence of LIF R in spermatogonia. By using Western blotting analysis, the presence of LIF and LIF R proteins was confirmed in porcine Leydig and Sertoli cells as early as 21 days post partum. To our knowledge, this is the first report on the in situ localization of LIF and LIF R proteins in the different testicular cell types during the postnatal development. Furthermore, in these testicular cells, we confirmed the expression of the genes through the presence of the LIF and LIF R mRNA by using the RT-PCR approach. LIF was detected in porcine Sertoli cells at 21 days post partum by RT-PCR and Western blot analyses but not by immunohistochemistry. These discrepancies could be attributable to a lower sensitivity of the immunohistochemical approach. Studies from other laboratories have also been performed to identify LIF and LIF R mRNA through RT-PCR and LIF bioactivity in the postnatal testicular cells (16, 53). These authors first isolated the different testicular cell types and then performed LIF and LIF R detection on each cell population (16, 53). Concerning LIF mRNA, it has been detected in Leydig cells, Sertoli cells, spermatogonia (16, 53), peritubular myoid cells, and macrophages (53) in rat and mouse models (16, 53). By using a bioassay, LIF activity was detected in peritubular myoid cells and Leydig cells under basal conditions (53). Concerning LIF R mRNA, it has been detected in Leydig cells, Sertoli cells, and pre- and postmeiotic germ cells (16). In our study, we also detected LIF R in germ cells but only in spermatogonia. These discrepancies could be attributable to a difference in sensitivity between the techniques used (immunohistochemistry vs. RT-PCR) or could be attributed to interspecies variations (porcine vs. murine models). Indeed, Jenab et al. (16) detected the LIF R mRNA in murine germ cells but not in rat germ cells. The LIF R detected in porcine testes was the membrane-bound form, because the primers used amplified only this form and because soluble LIF R was not detected in the testis (54). The gp130 protein, which is a LIF R partner for signal tranduction, was detected in rat Leydig, Sertoli, and germ cells (16), suggesting that LIF could directly interact with Leydig cells.

The presence of LIF and its receptor in both the neonatal and adult Leydig cells suggests that the inhibitory action of LIF on testosterone synthesis may occur during the testicular development in the fetal and adult Leydig cell populations. In this context, it will be of interest to determine how testicular LIF and LIF R expressions are modulated in physiological or pathological conditions. Specifically, the role of the gonadotropins and other local testicular signaling molecules affecting LIF and its receptors are currently being investigated in our laboratory.

In summary, by using cultured purified porcine Leydig cells as a model, this study has evidenced a novel role of LIF. The cytokine antagonizes the gonadotropin steroidogenic action at post-cAMP level(s) and, more specifically, at the level of the expression of StAR, a protein involved in cholesterol transport/availability into mitochondria.


    Acknowledgments
 
We are grateful to Dr. E. De Peretti for the steroid hormone assays, Mrs. M. A. Chauvin for technical assistance, and Mrs. A. Florin for her critical reading of the manuscript. We are grateful to Dr. D. Stocco for providing us with cDNA probe and antibody for StAR and to Dr. N. Vita for PBR antibody. We also thank Mr. P. Bouteille for providing us with porcine testes.


    Footnotes
 
1 This work was supported by Institut National de la Santé et de la Recherche Médicale (INSERM, U 407) and Ministère de la Recherche et de l’Enseignement Supérieur. Back

Received September 18, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Auernhammer CJ, Melmed S 2000 Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21:313–345[Abstract/Free Full Text]
  2. Metcalf D 1992 Role of hemopoietic growth factors in the development and suppression of myeloid leukemia. Leukemia [Suppl 3] 6:187S–188S
  3. Heath JK 1992 Cytokines. Can there be life without LIF? Nature 359:317
  4. Taupin JL, Pitard V, Dechanet J, Miossec V, Gualde N, Moreau JF 1998 Leukemia inhibitory factor: part of a large ingathering family. Int Rev Immunol 16:397–426[Medline]
  5. Escary JL, Perreau J, Dumenil D, Ezine S, Brulet P 1993 Leukaemia inhibitory factor is necessary for maintenance of haematopoietic stem cells and thymocyte stimulation. Nature 363:361–364[CrossRef][Medline]
  6. Bamberger AM, Schulte HM, Wullbrand A, Jung R, Beil FU, Bamberger CM 2000 Expression of leukemia inhibitory factor (LIF) and LIF receptor (LIF-R) in the human adrenal cortex: implications for steroidogenesis. Mol Cell Endocrinol 162:145–149[CrossRef][Medline]
  7. Stewart CL, Kaspar P, Brunet LJ, Bhatt H, Gadi I, Kontgen F, Abbondanzo SJ 1992 Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359:76–79[CrossRef][Medline]
  8. Vogiagis D, Salamonsen LA 1999 Review: the role of leukaemia inhibitory factor in the establishment of pregnancy. J Endocrinol 160:181–190[Abstract]
  9. Senturk LM, Arici A 1998 Leukemia inhibitory factor in human reproduction. Am J Reprod Immunol 39:144–151
  10. Coskun S, Uzumcu M, Jaroudi K, Hollanders JM, Parhar RS, al-Sedairy ST 1998 Presence of leukemia inhibitory factor and interleukin-12 in human follicular fluid during follicular growth. Am J Reprod Immunol 40:13–18
  11. Ozornek MH, Bielfeld P, Krussel JS, Hirchenhain J, Jeyendran RS, Koldovsky U 1999 Epidermal growth factor and leukemia inhibitory factor levels in follicular fluid. Association with in vitro fertilization outcome. J Reprod Med 44:367–369[Medline]
  12. Matsui Y, Toksoz D, Nishikawa S, Nishikawa S-I, Williams D, Zsebo KM, Hogan BLM 1991 The effect of steel factor, the ligand for c-kit and LIF/DIA on murine primordial germ cells in culture. Nature 353:750–752[CrossRef][Medline]
  13. Resnick JL, Bixler LS, Cheng L, Donovan PJ 1992 Long-term proliferation of mouse primordial germ cells in culture. Nature 35:550–552
  14. Pesce M, Farrace MG, Piacentini M, Dolci S, De Felici M 1993 Stem cell factor and leukemia inhibitory factor promote primordial germ cell survival by suppressing programmed cell death (apoptosis). Development 118:1089–1094[Abstract]
  15. De Miguel MP, De Boer-Brouwer M, Paniagua R, van den Hurk R, De Rooij DG, Van Dissel-Emiliani FM 1996 Leukemia inhibitory factor and ciliary neurotropic factor promote the survival of Sertoli cells and gonocytes in coculture system. Endocrinology 137:1885–1893[Abstract]
  16. Jenab S, Morris PL 1998 Testicular leukemia inhibitory factor (LIF) and LIF receptor mediate phosphorylation of signal transducers and activators of transcription (STAT)-3 and STAT-1 and induce c-fos transcription and activator protein-1 activation in rat Sertoli but not germ cells. Endocrinology 139:1883–1890[Abstract/Free Full Text]
  17. Mauduit C, Hartmann DJ, Chauvin MA, Revol A, Morera AM, Benahmed M 1991 Tumor necrosis factor a inhibits gonadotropin action in cultured porcine Leydig cells: site(s) of action. Endocrinology 129:2933–2940[Abstract]
  18. Mendelson C, Dufau M, Catt K 1975 Gonadotropin binding and stimulation of cyclic adenosine 3':5'- monophosphate and testosterone production in isolated Leydig cells. J Biol Chem 250:8818–8823[Abstract/Free Full Text]
  19. Orava M, Haour F, Leinonen P, Ruokonen A, Vihko R 1985 Relationships between unconjugated and sulphated steroids in porcine primary Leydig cell culture. J Steroid Biochem 22:507–512[CrossRef][Medline]
  20. Arthur JR, Blair HA, Boyd GS, Mason JI, Suckling KE 1976 Oxidation of cholesterol and cholesterol analogues by mitochondrial preparations of steroid-hormone-producing tissue. Biochem J 158:47–51[Medline]
  21. Forest MG, Cathiard AM, Bertrand J 1973 Total and unbound testosterone levels in the newborns and normal hypogonadal children: use of sensitive radioimmunoassay for testosterone. J Clin Endocrinol Metab 36:1132–1142[Medline]
  22. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal Biochem 162:156–159[Medline]
  23. Liscum L, Munn NJ 1999 Intracellular cholesterol transport. Biochim Biophys Acta 1438:19–37[Medline]
  24. Stocco DM 2000 Intramitochondrial cholesterol transfer. Biochim Biophys Acta 1486:184–197[Medline]
  25. Clark BJ, Soo SC, Caron KM, Ikeda Y, Parker KL, Stocco DM 1995 Hormonal and developmental regulation of the steroidogenic acute regulatory protein. Mol Endocrinol 9:1346–1355[Abstract]
  26. Clark BJ, Wells J, King SR, Stocco DM 1994 The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem 269:28314–28322[Abstract/Free Full Text]
  27. Lin D, Sugawara T, Strauss 3rd JF, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL 1995 Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267:1828–1831[Abstract/Free Full Text]
  28. Caron KM, Soo SC, Wetsel WC, Stocco DM, Clark BJ, Parker KL 1997 Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci USA 94:11540–11545[Abstract/Free Full Text]
  29. Arakane F, Sugawara T, Nishino H, Liu Z, Holt JA, Pain D, Stocco DM, Miller WL, Strauss 3rd JF 1996 Steroidogenic acute regulatory protein (StAR) retains activity in the absence of its mitochondrial import sequence: implications for the mechanism of StAR action. Proc Natl Acad Sci USA 93:13731–13736[Abstract/Free Full Text]
  30. Arakane F, King SR, Du Y, Kallen CB, Walsh LP, Watari H, Stocco DM, Strauss 3rd JF 1997 Phosphorylation of steroidogenic acute regulatory protein (StAR) modulates its steroidogenic activity. J Biol Chem 272:32656–32662[Abstract/Free Full Text]
  31. Papadopoulos V 1993 Peripheral-type benzodiazepine/diazepam binding inhibitor receptor: biological role in steroidogenic cell function. Endocr Rev 14:222–240[CrossRef][Medline]
  32. Anholt RR, De Souza EB, Oster-Granite ML, Snyder SH 1985 Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther 233:517–526[Abstract/Free Full Text]
  33. Papadopoulos V, Nowzari FB, Krueger KE 1991 Hormone-stimulated steroidogenesis is coupled to mitochondrial benzodiazepine receptors. Tropic hormone action on steroid biosynthesis is inhibited by flunitrazepam. J Biol Chem 266:3682–3687[Abstract/Free Full Text]
  34. Kelly-Hershkovitz E, Weizman R, Spanier I, Leschiner S, Lahav M, Weisinger G, Gavish M 1998 Effects of peripheral-type benzodiazepine receptor antisense knockout on MA-10 Leydig cell proliferation and steroidogenesis. J Biol Chem 273:5478–5483[Abstract/Free Full Text]
  35. Culty M, Li H, Boujrad N, Amri H, Vidic B, Bernassau JM, Reversat JL, Papadopoulos V 1999 In vitro studies on the role of the peripheral-type benzodiazepine receptor in steroidogenesis. J Steroid Biochem Mol Biol 69:123–130[CrossRef][Medline]
  36. Rey C, Mauduit C, Naureils O, Benahmed M, Louisot P, Gasnier F 2000 Up-regulation of mitochondrial peripheral benzodiazepine receptor expression by tumor necrosis factor alpha in testicular leydig cells. Possible involvement in cell survival. Biochem Pharmacol 60:1639–1646[CrossRef][Medline]
  37. Ogilvie KM, Held Hales K, Roberts ME, Hales DB, Rivier C 1999 The inhibitory effect of intracerebroventricularly injected interleukin 1beta on testosterone secretion in the rat: role of steroidogenic acute regulatory protein. Biol Reprod 60:527–533[Abstract/Free Full Text]
  38. Mauduit C, Gasnier F, Rey C, Chauvin MA, Stocco DM, Louisot P, Benahmed M 1998 Tumor necrosis factor-alpha inhibits leydig cell steroidogenesis through a decrease in steroidogenic acute regulatory protein expression. Endocrinology 139:2863–2868[Abstract/Free Full Text]
  39. Lin T, Hu J, Wang D, Stocco DM 1998 Interferon-gamma inhibits the steroidogenic acute regulatory protein messenger ribonucleic acid expression and protein levels in primary cultures of rat Leydig cells. Endocrinology 139:2217–2222[Abstract/Free Full Text]
  40. Hales KH, Diemer T, Ginde S, Shankar BK, Roberts M, Bosmann HB, Hales DB 2000 Diametric effects of bacterial endotoxin lipopolysaccharide on adrenal and Leydig cell steroidogenic acute regulatory protein. Endocrinology 141:4000–4012[Abstract/Free Full Text]
  41. Lin T, Wang D, Hu J, Stocco DM 1998 Up-regulation of human chorionic gonadotrophin-induced steroidogenic acute regulatory protein by insulin-like growth factor-I in rat Leydig cells. Endocrine 8:73–78[CrossRef][Medline]
  42. Huang BM, Stocco DM, Li PH, Yang HY, Wu CM, Norman RL 1997 Corticotropin-releasing hormone stimulates the expression of the steroidogenic acute regulatory protein in MA-10 mouse cells. Biol Reprod 57:547–551[Abstract]
  43. Manna PR, Tena-Sempere M, Huhtaniemi IT 1999 Molecular mechanisms of thyroid hormone-stimulated steroidogenesis in mouse leydig tumor cells. Involvement of the steroidogenic acute regulatory (StAR) protein. J Biol Chem 274:5909–5918[Abstract/Free Full Text]
  44. Kanzaki M, Morris PL 1999 Growth hormone regulates steroidogenic acute regulatory protein expression and steroidogenesis in Leydig cell progenitors. Endocrinology 140:1681–1686[Abstract/Free Full Text]
  45. Lee HK, Yoo MS, Choi HS, Kwon HB, Soh J 1999 Retinoic acids up-regulate steroidogenic acute regulatory protein gene. Mol Cell Endocrinol 148:1–10[CrossRef][Medline]
  46. Walsh LP, Stocco DM 2000 Effects of lindane on steroidogenesis and steroidogenic acute regulatory protein expression. Biol Reprod 63:1024–1033[Abstract/Free Full Text]
  47. Walsh LP, Webster DR, Stocco DM 2000 Dimethoate inhibits steroidogenesis by disrupting transcription of the steroidogenic acute regulatory (StAR) gene. J Endocrinol 167:253–263[Abstract]
  48. Carter-Su C, Smit LS 1998 Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Recent Prog Horm Res 53:61–82
  49. Schiemann WP, Nathanson NM 1994 Involvement of protein kinase C during activation of the mitogen-activated protein kinase cascade by leukemia inhibitory factor. Evidence for participation of multiple signaling pathways. J Biol Chem 269:6376–6382[Abstract/Free Full Text]
  50. Caron KM, Ikeda Y, Soo SC, Stocco DM, Parker KL, Clark BJ 1997 Characterization of the promoter region of the mouse gene encoding the steroidogenic acute regulatory protein. Mol Endocrinol 11:138–147[Abstract/Free Full Text]
  51. Sugawara T, Holt JA, Kiriakidou M, Strauss 3rd JF 1996 Steroidogenic factor 1-dependent promoter activity of the human steroidogenic acute regulatory protein (StAR) gene. Biochemistry 35:9052–9059[CrossRef][Medline]
  52. Clark BJ, Combs R 1999 Angiotensin II and cyclic adenosine 3',5'-monophosphate induce human steroidogenic acute regulatory protein transcription through a common steroidogenic factor-1 element. Endocrinology 140:4390–4398[Abstract/Free Full Text]
  53. Piquet-Pellorce C, Dorval-Coiffec I, Pham MD, Jegou B 2000 Leukemia inhibitory factor expression and regulation within the testis. Endocrinology 141:1136–1141[Abstract/Free Full Text]
  54. Michel D, Chatelain G, Mauduit C, Benahmed M, Brun G 1997 Recent evolutionary acquisition of alternative pre-mRNA splicing and 3' processing regulations induced by intronic B2 SINE insertion. Nucleic Acids Res 25:3228–3234[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
P. Magni, E. Dozio, M. Ruscica, H. Watanobe, A. Cariboni, R. Zaninetti, M. Motta, and R. Maggi
Leukemia Inhibitory Factor Induces the Chemomigration of Immortalized Gonadotropin-Releasing Hormone Neurons through the Independent Activation of the Janus Kinase/Signal Transducer and Activator of Transcription 3, Mitogen-Activated Protein Kinase/Extracellularly Regulated Kinase 1/2, and Phosphatidylinositol 3-Kinase/Akt Signaling Pathways
Mol. Endocrinol., May 1, 2007; 21(5): 1163 - 1174.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. H. Volle, K. Mouzat, R. Duggavathi, B. Siddeek, P. Dechelotte, B. Sion, G. Veyssiere, M. Benahmed, and J.-M. A. Lobaccaro
Multiple Roles of the Nuclear Receptors for Oxysterols Liver X Receptor to Maintain Male Fertility
Mol. Endocrinol., May 1, 2007; 21(5): 1014 - 1027.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R.-S. Ge, Q. Dong, C. M. Sottas, V. Papadopoulos, B. R. Zirkin, and M. P. Hardy
In search of rat stem Leydig cells: Identification, isolation, and lineage-specific development
PNAS, February 21, 2006; 103(8): 2719 - 2724.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
R.-S. Ge, Q. Dong, C. M. Sottas, H. Chen, B. R. Zirkin, and M. P. Hardy
Gene Expression in Rat Leydig Cells During Development from the Progenitor to Adult Stage: A Cluster Analysis
Biol Reprod, June 1, 2005; 72(6): 1405 - 1415.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
I. Dorval-Coiffec, J.-G. Delcros, H. Hakovirta, J. Toppari, B. Jegou, and C. Piquet-Pellorce
Identification of the Leukemia Inhibitory Factor Cell Targets Within the Rat Testis
Biol Reprod, March 1, 2005; 72(3): 602 - 611.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
A Bozec, F Chuzel, S Chater, C Paulin, R Bars, M Benahmed, and C Mauduit
The mitochondrial-dependent pathway is chronically affected in testicular germ cell death in adult rats exposed in utero to anti-androgens
J. Endocrinol., October 1, 2004; 183(1): 79 - 90.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Omezzine, S. Chater, C. Mauduit, A. Florin, E. Tabone, F. Chuzel, R. Bars, and M. Benahmed
Long-Term Apoptotic Cell Death Process with Increased Expression and Activation of Caspase-3 and -6 in Adult Rat Germ Cells Exposed in Utero to Flutamide
Endocrinology, February 1, 2003; 144(2): 648 - 661.
[Abstract] [Full Text]